Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Philippines, the Russian Federation, and Mexico

Condition:   Healthy Volunteers (Meningococcal Infection) Interventions:   Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine;   Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine;   Biological: Measles, Mumps, and Rubella Virus Vaccine L ive;   Biological: Varicella Virus Vaccine;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Biological: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine;   Biological: Diphtheria, Teta nus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine;   Biological: Hepatitis B Vaccine;   Biological: Rotavirus Vaccine, Live, Pentavalent;   Biological: Japanese encephalitis vaccine (live, attenuated) Sponsor:   Sanofi Pasteur, a Sanofi Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials